Smith, Moore & Co’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Smith, Moore & Co’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,880	Closed	-$149K	–	389
2022 Q3	$149K	Buy	+14,880	New	+$148K	0.02%	359

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Smith, Moore & Co's PKBO Position: Q4 2022 in Review

Smith, Moore & Co sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 14,880 shares — an estimated $149K sold.

Smith, Moore & Co first reported a position in PKBO in Q3 2022 and held it in 1 quarter. The position peaked at $149K in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Smith, Moore & Co reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Smith, Moore & Co sold 14,880 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $149K.
Smith, Moore & Co first reported a position in Peak Bio, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
Smith, Moore & Co's Peak Bio, Inc. Common Stock position peaked at $149K in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Smith, Moore & Co's 13F filing for Q4 2022, filed 13 Feb 2023.